Delayed Nasdaq Stockholm 06:54:44 2024-04-30 EDT 5-day change 1st Jan Change
8.1 SEK +1.50% Intraday chart for Iconovo AB +1.25% -29.87%

Financials

Sales 2023 7.08M 644K 887K Sales 2024 * 45.65M 4.15M 5.72M Capitalization 95.22M 8.66M 11.93M
Net income 2023 -45M -4.09M -5.64M Net income 2024 * -26M -2.36M -3.26M EV / Sales 2023 16.6 x
Net cash position 2023 18.48M 1.68M 2.32M Net cash position 2024 * 38.6M 3.51M 4.84M EV / Sales 2024 * 1.24 x
P/E ratio 2023
-2.63 x
P/E ratio 2024 *
-4.05 x
Employees 31
Yield 2023 *
-
Yield 2024 *
-
Free-Float 36.29%
More Fundamentals * Assessed data
Dynamic Chart
Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone CI
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease CI
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers CI
Iconovo Receives Order from Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler CI
Arcede Pharma and Iconovo AB Takes the Next Step in the Development of a New Treatment for COPD CI
Iconovo AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Iconovo AB Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone CI
Iconovo AB Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations CI
Iconovo AB Launches Outreach Phase in Structured Process for Out-Licensing of ICOpre CI
Iconovo AB Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027 CI
Iconovo to Launch Pharmacokinetic Study for Inhalable Treatment Under Kiox Pharma Partnership MT
Iconovo AB Receives Additional Development Contract from Kiox Pharma for New Inhalable Treatment Against Rare Disease CI
More news
1 day+1.50%
1 week+1.25%
Current month-6.03%
1 month-6.03%
3 months-22.12%
6 months-22.12%
Current year-29.87%
More quotes
1 week
7.56
Extreme 7.56
8.46
1 month
7.50
Extreme 7.5
9.00
Current year
7.46
Extreme 7.46
12.55
1 year
7.46
Extreme 7.46
40.00
3 years
7.46
Extreme 7.46
99.80
5 years
7.46
Extreme 7.46
99.80
10 years
7.46
Extreme 7.46
99.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 20-04-13
Founder 60 12-12-31
Director of Finance/CFO 61 23-03-31
Members of the board TitleAgeSince
Founder 63 12-12-31
Chairman 65 21-04-30
Director/Board Member 58 20-12-31
More insiders
Date Price Change Volume
24-04-30 8.1 +1.50% 40,641
24-04-29 7.98 +2.84% 102,465
24-04-26 7.76 -3.00% 72,437
24-04-25 8 -1.23% 85,100
24-04-24 8.1 +2.79% 40,587

Delayed Quote Nasdaq Stockholm, April 30, 2024 at 06:54 am

More quotes
Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Company’s device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings